Another study demonstrated that treatment using the MyD88 inhibitor (ST2825) resulted in reduced growth of murine mammary carcinomas 4T1, 168, EMT6, and SM1, as well as the human breast cancer cell line MDA-MB-231 (36). This evidence concerns the gene MYD88 and breast carcinoma.